Tumorigenesis is the process involved in the production of a new tumor or tumors.
A molecule that controls intestinal cell growth plays a dual role maintaining gut health and promoting diseases such as cancer, says a study in eLife.
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this research gained attention for using a systems biology approach, which is an integrated research area of IT and BT.
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs.
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer than any other gene.
Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer carries mutations in the p53 gene.
In an innovative approach to colorectal cancer (CRC) prevention and treatment, scientists are studying ways to replace missing metabolites in patients prone to gut inflammation and CRC.
Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations.
Aging is the continuing process of such stress exposures, and with advancing age (normal aging), we must carry lots of senescent cells within our bodies. Senescent cells also often provide some ‘bad influences’ to surrounding healthy cells; such as chronic inflammation and tumorigenesis
The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies.
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy, and radiation.
Many potent anti-cancer drugs have major drawbacks -- they fail to mix with water, which means they will have a limited solubility in blood, and they lack selectivity to cancer cells.
A research group from the University of Seville has revealed the role that the protein Rrm3 plays in the repair of breaks that occur during the replication of DNA, by using the yeast Saccharomyces cerevisiae as a model organism.
Current view is that cancer development is initiated from cells that acquire initial DNA mutations. These in turn provoke additional defects, and ultimately the affected cells begin to proliferate in an uncontrolled manner to develop primary tumors.
Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue.
The low oxygen concentrations that prevail in many tumors enhance their propensity to metastasize to other tissues. Researchers at Ludwig-Maximilians-Universitaet in Munich led by Professor Heiko Hermeking have now uncovered the molecular mechanism that links the two phenomena.
Identification and functional validation of proteins involved in tumorigenesis are essential steps toward advancing cancer precision medicine. In The Journal of Clinical Investigation researchers from VIB, KU Leuven together with colleagues from INSERM now report the important role for FES in the initiation and progression of melanoma, a malignant type of skin cancer, that is notoriously quick to metastasize and that responds poorly to existing cancer treatments.
After five years of hard work, China has completed the world's largest kinase-based whole-cell screening library for high-throughput drug assay.
The malignant transformation of hepatocytes is the origin of most hepatocellular carcinomas, an aggressive type of liver cancer with high mortality rates. But these cells do not act alone.
The gene p53 is the most commonly mutated gene in cancer - it is p53's job to monitor cells for DNA damage and to mark damaged cells for destruction and so cancer cells with mutated DNA must disable p53 before it disables them.
Nearly 50 years into the "war" on cancer, doctors possess weapons that once would have seemed magical in their tumor-killing specificity.